NLM Logo

Nivolumab MeSH Descriptor Data 2022


MeSH Heading
Nivolumab
Tree Number(s)
D12.776.124.486.485.114.224.060.829
D12.776.124.790.651.114.224.060.829
D12.776.377.715.548.114.224.200.829
Unique ID
D000077594
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077594
Scope Note
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
Entry Term(s)
BMS-936558
MDX-1106
ONO-4538
Opdivo
Pharm Action
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Registry Number
31YO63LBSN
Public MeSH Note
2019; NIVOLUMAB was indexed under ANTIBODIES, MONOCLONAL 2010-2018
History Note
2019 (2010)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2020/02/28
Nivolumab Preferred
Opdivo Narrower
ONO-4538 Narrower
MDX-1106 Narrower
BMS-936558 Narrower
page delivered in 0.139s